9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue Reading[video width="600" height="200" mp4="/wp-content/uploads/2024/09/ICDS-2024-header-recap.mp4" poster="/wp-content/uploads/2024/09/ICDS-2024-header-recap.jpg"][/video] Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller led the End Points in Clinical Trials session, where...